Joint disease and osteoarthritis (OA) are common causes of impaired performance and economic wastage in the equine industry. Traditional therapy often targets symptom modification through the use of either locally or systemically administered agents that can help control some of the symptoms of pain and impaired function associated with joint health challenges (corticosteroids and non-steroidal anti-inflammatory drugs [NSAIDS]). But beyond intervention and symptom-modifying approaches to joint disease, preventive approaches have become more popular. Working toward this goal, some injectable products, like hyaluronan (HA) and polysulfated glycosaminoglycan, have been developed. But oral nutraceutical supplements are based on a nutritional, preventive approach to joint health challenges, and some products have undergone clinical trials documenting improvement in the symptoms of stiffness and soreness that accompanies joint disease.